COMPANY RESEARCHHinova Pharmaceuticals, Inc.
Hinova Pharmaceuticals is a China-based company involved in innovative medicine discovery, development and commercialization. Its research interests include oncology, metabolic disorders, autoimmune diseases and chronic inflammatory conditions. The company pursues small-molecule therapeutic approaches and differentiated drug-development strategies. Its official website identifies its Shanghai STAR Market securities code as 688302. Hinova's pharmaceutical activities encompass research into disease biology, candidate selection and clinical development, alongside industrialization planning for drug products. Its therapeutic focus differentiates the company from manufacturers solely producing established generic medicines or organizations limited to contract research services. The company operates within China's publicly listed innovative-drug development sector.
Company at a glance
Corporate information
- Company entity
- 海创药业股份有限公司／Hinova Pharmaceuticals
- Headquarters / principal office
- Chengdu, Sichuan, ChinaCorporate website explicitly identifies headquarters; location follows the retrieved disclosure.
Sources (1)
- Official company contact / corporate location disclosureChecked 2026-11-04; source publication date retained where stated
- Founded
- 2013
Sources (1)
- Our Company／Development and MilestonesNot stated
- Ownership / capital status
- Publicly tradedPublicly traded
Sources (1)
- Our Company／Development and MilestonesNot stated
- Official corporate reference
- https://www.hinovapharma.com/en/
Sources (1)
- Our Company／Development and MilestonesNot stated
- LinkedIn company page
- LinkedIn ↗
Sources (1)
- Hinova Pharmaceuticals 公司主页Not stated
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Hinova Pharmaceuticals is a China-based company involved in innovative medicine discovery, development and commercialization. Its research interests include oncology, metabolic disorders, autoimmune diseases and chronic inflammatory conditions. The company pursues small-molecule therapeutic approaches and differentiated drug-development strategies. Its official website identifies its Shanghai STAR Market securities code as 688302. Hinova's pharmaceutical activities encompass research into disease biology, candidate selection and clinical development, alongside industrialization planning for drug products. Its therapeutic focus differentiates the company from manufacturers solely producing established generic medicines or organizations limited to contract research services. The company operates within China's publicly listed innovative-drug development sector.
SSE STAR: 688302
targeted protein degradation · PROTAC · deuterated medicines
oncology · metabolic disease · autoimmune disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
The website identifies HP518 as an oral AR PROTAC. Enrollment in China Phase 2 is complete, Australian Phase 1 is complete, and China combination Phase 1/2 authorization was obtained in November 2025.
Business, technology & evidence
- Hinova Pharmaceuticals is a China-based company involved in innovative medicine discovery, development and commercialization. Its research interests include oncology, metabolic disorders, autoimmune diseases and chronic inflammatory conditions. The company pursues small-molecule therapeutic approaches and differentiated drug-development strategies. Its official website identifies its Shanghai STAR Market securities code as 688302. Hinova's pharmaceutical activities encompass research into disease biology, candidate selection and clinical development, alongside industrialization planning for drug products. Its therapeutic focus differentiates the company from manufacturers solely producing established generic medicines or organizations limited to contract research services. The company operates within China's publicly listed innovative-drug development sector.
- SecuritiesSSE STAR: 688302
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| HP518 | AR · Prostate cancer | Phase 2 | Human results reported by the source; see facts and original materials for type and quality |
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Company progress statements do not replace complete clinical study reports. HP537's specific degradation mechanism and latest status require separate verification.
- Our Company / HP518 milestones ↗Hinova · Undated · 2026-10-31accessed
- HP518Product pipeline ↗Hinova Pharmaceuticals · Undated · 2026-10-31accessed
- Official issuer and R&D disclosure · Hinova Pharmaceuticals, Inc. ↗Hinova Pharmaceuticals, Inc. ·
- Hinova Pharmaceuticals 公司主页 ↗Hinova／LinkedIn · Not stated
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.